Navigation Links
Galderma Completes Tender Offer for CollaGenex
Date:4/7/2008

date the information included in this press release or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Restoraderm(R), SansRosa(R) and Oracea(R) are registered trademarks and IMPACS(TM) is a trademark of CollaGenex Pharmaceuticals, Inc.

Novacort(R) and Alcortin(R) A are trademarks of Primus Pharmaceuticals, Inc.

Differin(R), Metrogel(R), Clobex(R), Tri-Luma(R), Cetaphil(R) and Epiduo(R) are trademarks of Galderma Pharma S.A.

Pliaglis(R) is a trademark of Zars Pharma Inc. and Dysport(R) is a trademark of Ipsen Ltd.

All other trade names, trademarks or service marks are the property of their respective owners and are not the property of CollaGenex Pharmaceuticals, Inc. or any of our subsidiaries.


'/>"/>
SOURCE Galderma Pharma S.A.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Galderma Announces HSR Clearance for Its Proposal to Acquire CollaGenex Pharmaceuticals
2. ZARS Pharma Announces Worldwide License Agreement With Galderma Pharma S.A. for Pliaglis(TM), a Topical Local Anesthetic
3. Galderma Pharma, S.A. and ZARS Pharma, Inc. Extend Agreement to Cover Worldwide Rights for Pliaglis(TM)
4. Galderma Reaches Agreement to Acquire CollaGenex Pharmaceuticals
5. Galderma Associates Itself to Cartiers Womens Initiative Awards to Recognize Female Entrepreneurs From Around the Globe
6. ProGenTech Completes $21 Million Series C Financing
7. KV Pharmaceutical Company Completes Financial Restatement with the Filing of Fiscal 2007 Form 10-K
8. Payformance Completes Sale of Corporate Payments Division
9. PreMD Inc. Completes Debenture Financing
10. Gentiva(R) Health Services Completes Acquisition of Major Home Health Provider in CON State of Mississippi
11. Roche Completes Tender Offer for Ventana Shares
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2009)... study by researchers from the Medical College of Wisconsin, ... for pain and other sickle cell disease complications in ... both providers and patients were also identified. The ... professor of pediatrics at the Medical College and Children,s ... be presented at the American Society of Hematology meeting ...
(Date:12/6/2009)... clotting, or coagulation, is an important process that ... injured. Sometimes, however, clots form on the inside ... not dissolve naturally, a potentially life-threatening situation requiring ... Meeting of the American Society of Hematology reveals ... and heparin with the hope of preventing clots ...
(Date:12/6/2009)... of the community, in cooperation with the Greater VA Healthcare System ... This year,s attendance is expected to soar to more than 5,000 ... ... (PRWEB) December 6, 2009 -- Volunteer organizations and members ... in West Los Angeles, will once again create a holiday party. ...
(Date:12/5/2009)... There have been significant scientific advances in the ... gain a better understanding of how certain diseases progress ... patients with the best care. Research presented today at ... Hematology explores optimal induction therapies for managing multiple myeloma, ...
(Date:12/5/2009)... Type of Blood Cancer Is Most Challenging-- ... oncologists have identified specific genes, dubbed partner genes, that ... of leukemia in infants. By more accurately defining specific ... may benefit from particular treatments. ,, Oncologists also ...
Breaking Medicine News(10 mins):Health News:New study finds barriers to pain treatment in children with sickle cell disease 2Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 2Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 3Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 4Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 5Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 6Health News:Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages 7Health News:17th Annual Event Honoring 5,000 + Veterans, Military Personnel to Include Real Life “Heroes” 2Health News:17th Annual Event Honoring 5,000 + Veterans, Military Personnel to Include Real Life “Heroes” 3Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 2Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 3Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 4Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 5Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 6Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 7Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 8Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 2Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 3Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 4
... Software) will be subsidized in the recently passed Economic Stimulus plan. ... be increased level of patient care. This will happen as ... centralized patient database, increased health maintenance care, and portability of data. ... ...
... Since 1998, Deals at a 13-Year Low; VCs Making ... and NEW YORK, April 18 New data from ... industry continued to contract in the first quarter of ... U.S. companies in the quarter, a 50% decline from ...
... Cross, UN Foundation site trends indicating measles risk ... in four states - California, Pennsylvania, Maryland and ... adults and children living in the United States ... global spread of the disease.(Logo: ...
... clinical and education programs for children, families and future ... System,s Center for Exceptional Families (CEF) and the ... celebrated the grand opening of their new shared facility ... Radio Disney AM 910 Road Crew. Mike Galante, ...
... Medication known as PTU can cause liver disease, experts say ... restrict the use of the antithyroid drug (PTU) in children ... letter to the editor in the April 9 New ... can cause severe liver disease in children and should no ...
... come from fertility clinic embryos that otherwise would be ... hoping to use U.S. funding for embryonic stem cell ... otherwise would be discarded, the National Institutes of Health ... controversial research -- such as using stem cells taken ...
Other Medicine News:Health News:Medical EMR Software To Be Subdized In Pres. Obama's Economic Stimulus Plan - Lives Can Be Saved As A Result 2Health News:Medical EMR Software To Be Subdized In Pres. Obama's Economic Stimulus Plan - Lives Can Be Saved As A Result 3Health News:U.S. Venture Investment Lowest in 11 Years, Down 50% to $3.9 Billion in First Quarter 2Health News:U.S. Venture Investment Lowest in 11 Years, Down 50% to $3.9 Billion in First Quarter 3Health News:U.S. Venture Investment Lowest in 11 Years, Down 50% to $3.9 Billion in First Quarter 4Health News:U.S. Venture Investment Lowest in 11 Years, Down 50% to $3.9 Billion in First Quarter 5Health News:U.S. Measles Outbreaks Highlight Global Need 2Health News:Oakwood Healthcare and UM-Dearborn Welcome the Community to Their New Dearborn Facility 2Health News:Oakwood Healthcare and UM-Dearborn Welcome the Community to Their New Dearborn Facility 3Health News:Drug May Be Dangerous for Kids With Graves' Disease 2Health News:NIH May Ease Some, But Not All, Stem Cell Restrictions 2Health News:NIH May Ease Some, But Not All, Stem Cell Restrictions 3Health News:NIH May Ease Some, But Not All, Stem Cell Restrictions 4
(Date:12/4/2009)... Shore and E. David Crawford presented results for prostate-specific ... end points of biochemical recurrence rate in a Phase ... or monthly leuprolide in prostate cancer patients during the ... received FIRMAGON 240/80 mg/month had a recurrence rate of ...
(Date:12/3/2009)... Allen Medical Systems, a subsidiary of Hill-Rom Holdings, Inc. ... of its new Allen Amatech(TM) OEM (Original Equipment Manufacturer) ... The website reinforces the Allen Amatech(TM) brand identity and ... with detailed descriptions and design specifications for the products. ...
(Date:12/3/2009)... 3 BioMed Realty Trust, Inc. (NYSE: BMR ... lease with Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN ) for ... space at The Landmark at Eastview campus in Tarrytown, New ... lease of additional space was completed approximately two months after ...
Breaking Medicine Technology:Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 2Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 3Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 4Allen Medical Systems Announces the Launch of New Allen Amatech(TM) OEM Website 2BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark 2BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark 3Nuvilex Renews MedX Master Distribution Agreement and Implements New Pricing for Talsyn Scar Cream 49191 1Nuvilex Renews MedX Master Distribution Agreement and Implements New Pricing for Talsyn Scar Cream 49191 2Nuvilex Renews MedX Master Distribution Agreement and Implements New Pricing for Talsyn Scar Cream 49191 3NxStage 28R 29 Announces Medisystems 28R 29 Bloodline Distribution Agreement with Gambro 49188 1NxStage 28R 29 Announces Medisystems 28R 29 Bloodline Distribution Agreement with Gambro 49188 2NxStage 28R 29 Announces Medisystems 28R 29 Bloodline Distribution Agreement with Gambro 49188 3Echo Therapeutics and Handok Pharmaceuticals Sign South Korea License for Needle free Symphony 28TM 29 Transdermal Continuous Glucose Monitoring Syste 49185 1Echo Therapeutics and Handok Pharmaceuticals Sign South Korea License for Needle free Symphony 28TM 29 Transdermal Continuous Glucose Monitoring Syste 49185 2Echo Therapeutics and Handok Pharmaceuticals Sign South Korea License for Needle free Symphony 28TM 29 Transdermal Continuous Glucose Monitoring Syste 49185 3Echo Therapeutics and Handok Pharmaceuticals Sign South Korea License for Needle free Symphony 28TM 29 Transdermal Continuous Glucose Monitoring Syste 49185 4
... QMed, Inc.,(Nasdaq: QMED ) today announced it ... the Centers for Medicare and Medicaid Services (CMS) ... Northern,California., In 2002, The CMS selected 15 ... coordinated care services to Medicare fee-for-service,beneficiaries with complex ...
... Promise, Enbrel Will Remain the Clinical Gold Standard Through 2016, ... ... Resources, WALTHAM, Mass., April 7, 2008 Decision Resources, one,of ... issues, finds that a drug,s effect on,inhibiting/slowing the progression of structural ...
Other Medicine Technology:QMed, Inc. Receives 2-Year Extension of Medicare Coordinated Care Demonstration Project by CMS 2Current and Emerging Drugs Have No Advantage Over Enbrel in Inhibiting/Slowing the Progression of Rheumatoid Arthritis 2Current and Emerging Drugs Have No Advantage Over Enbrel in Inhibiting/Slowing the Progression of Rheumatoid Arthritis 3
Sterile squares of smooth foil for repair of the floor of the orbit and other plastic surgery. Available in large size....
Clear Base Stand Magnifiers are ideal for any visual task that requires high magnification....
Bausch & Lomb magnifiers incorporates precision optics and patented ergonomic designs for increased clarity and comfort during use....
Ultra Thin Sheet. Medpor Sheets are commonly used for orbital floor reconstruction and other craniofacial applications....
Medicine Products: